Arbitrage SBIR Vendor Selection via FOIA-Powered CRO Matchmaking Platform
- Organization
- NSF SBIR program's structural gap between funding allocation and vendor intelligence provision
- Sector
- Specialized Contract Research Organizations seeking qualified SBIR-funded clients with guaranteed budgets
- Location
- National (US-focused)
Source reference
Executive summary
Current state
NSF awarded $305,000 SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a PKU microbiome therapeutic platform, creating a 6-month window where the company must prove technical feasibility but lacks strategic guidance, vendor intelligence, and IP protection for the critical Phase II transition required for survival.
Market catalyst
The arbitrage between ENDURE's immediate $305k cash (with 6-month expiration) and their complete lack of time/connections to identify and vet CROs with proven SBIR Phase II success rates. The SBIR system gives money but no vendor intelligence, creating a 15-25% margin opportunity for curated access.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.